Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI

被引:90
作者
Auray-Blais, Christiane [1 ]
Bherer, Patrick [1 ]
Gagnon, Rene [1 ]
Young, Sarah P. [2 ]
Zhang, Haoyue H. [2 ]
An, Yan [2 ]
Clarke, Joe T. R. [1 ]
Millington, David S. [2 ]
机构
[1] Univ Sherbrooke, Serv Genet, Dept Pediat, Fac Med & Hlth Sci, Sherbrooke, PQ J1H 5N4, Canada
[2] Duke Univ, Med Ctr, Div Med Genet, Dept Pediat, Durham, NC 27713 USA
关键词
Mucopolysaccharidosis; Dermatan sulfate; Heparan sulfate; High-risk screening; Urine; Liquid chromatography-tandem mass spectrometry; LC-MS/MS; MPS I; MPS II; MPS VI; Biomarker; TANDEM MASS-SPECTROMETRY; LYSOSOMAL STORAGE DISORDERS; ENZYME REPLACEMENT THERAPY; DRIED BLOOD SPOTS; FABRY-DISEASE; OLIGOSACCHARIDES; DISACCHARIDES; ASSAY;
D O I
10.1016/j.ymgme.2010.09.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mucopolysaccharidoses (MPSs) are complex storage disorders caused by specific lysosomal enzyme deficiencies, resulting in the accumulation of glycosaminoglycans (GAGS) in urine, plasma, as well as in various tissues. We devised and validated a straightforward, but accurate and precise tandem mass spectrometry methodology coupled to high performance liquid chromatography (LC-MS/MS) for the quantification of GAGs in urine. The method is applicable to the investigation of patients with MPS I, II, and VI, by quantifying dermatan sulfate (DS) and heparan sulfate (HS) in urine. We analyzed urine samples from 28 MPS patients, aged 1 to 42 years, and 55 control subjects (41 days to 18 years old). Levels of DS and HS in urine from healthy controls of all ages were below the limit of quantification. The levels of DS and HS in urine from 6 treated patients with MPS I were lower than in 6 untreated patients in DS (0.7-45 vs 9.3-177 mg/mmol creat) and HS (0-123 mg/mmol creatinine vs 38-418 mg/mmol creatinine); similar results were obtained for 9 patients with MPS II and 7 patients with MPS VI. Analyses were performed on as little as 250 mu L of urine. Methanolysis took 75 min per sample; the total analysis run time for each LC-MS/MS injection was 8 min. Results indicate that the method is applicable to a wide variety of situations in which high accuracy and precision are required, including the evaluation of the effectiveness of existing and emerging treatments. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:49 / 56
页数:8
相关论文
共 40 条
[1]   Replacement therapy in Mucopolysaccharidosis type VI: advantages of early onset of therapy [J].
Auclair, D ;
Hopwood, JJ ;
Brooks, DA ;
Lemontt, JF ;
Crawley, AC .
MOLECULAR GENETICS AND METABOLISM, 2003, 78 (03) :163-174
[2]   Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease [J].
Auray-Blais, C. ;
Cyr, D. ;
Mills, K. ;
Giguere, R. ;
Drouin, R. .
JOURNAL OF INHERITED METABOLIC DISEASE, 2007, 30 (01) :106-106
[3]   Quebec neonatal mass urinary screening programme: From micromolecules to macromolecules [J].
Auray-Blais, C. ;
Cyr, D. ;
Drouin, R. .
JOURNAL OF INHERITED METABOLIC DISEASE, 2007, 30 (04) :515-521
[4]   Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease [J].
Auray-Blais, C. ;
Millington, D. S. ;
Young, S. P. ;
Clarke, J. T. R. ;
Schiffmann, R. .
JOURNAL OF INHERITED METABOLIC DISEASE, 2009, 32 (02) :303-308
[5]   Mass urinary screening for Fabry disease: Is it feasible? [J].
Auray-Blais, Christiane ;
Cyr, Denis ;
Clarke, Joe T. R. ;
Drouin, Rigen .
MOLECULAR GENETICS AND METABOLISM, 2008, 93 (02) :S15-S15
[6]   Gb3/creatinine biomarkers for Fabry disease: Issues to consider [J].
Auray-Blais, Christiane ;
Millington, David S. ;
Barr, Caroline ;
Young, Sarah P. ;
Mills, Kevin ;
Clarke, Joe T. R. .
MOLECULAR GENETICS AND METABOLISM, 2009, 97 (03) :237-237
[7]   Fabry disease urinary globotriaosylceramide/creatinine biomarker evaluation by liquid chromatography-tandem mass spectrometry in healthy infants from birth to 6 months [J].
Barr, Caroline ;
Clarke, Joe T. R. ;
Ntwari, Aime ;
Drouin, Regen ;
Auray-Blais, Christiane .
MOLECULAR GENETICS AND METABOLISM, 2009, 97 (04) :278-283
[8]   SCREENING FOR MUCOPOLYSACCHARIDE DISORDERS WITH THE BERRY SPOT-TEST [J].
BERRY, HK .
CLINICAL BIOCHEMISTRY, 1987, 20 (05) :365-371
[9]   Application of tandem mass spectrometry to biochemical genetics and newborn screening [J].
Carpenter, KH ;
Wiley, V .
CLINICA CHIMICA ACTA, 2002, 322 (1-2) :1-10
[10]  
CHASSON A L, 1960, Tech Bull Regist Med Technol, V30, P207